University of Texas Texas AM Investment Management Co. Trims Stock Holdings in Eli Lilly and Company $LLY

Key Points

• University of Texas Texas AM Investment Management Co. cut its Eli Lilly stake by 93.5% in the fourth quarter, selling 5,878 shares and leaving it with 409 shares worth about $440,000.
• Despite that sale, institutional interest remains strong, with hedge funds and other investors owning 82.53% of Eli Lilly’s stock and several firms recently opening new positions.
• Analysts remain bullish on Eli Lilly overall: multiple firms reiterated buy-style ratings, the consensus view is “Moderate Buy,” and the average price target is $1,227.74.

University of Texas Texas AM Investment Management Co. decreased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 93.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 409 shares of the company's stock after selling 5,878 shares during the period. University of Texas Texas AM Investment Management Co.'s holdings in Eli Lilly and Company were worth $440,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. LFG Wealth Partners LLC purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth about $2,384,000. Sofinnova Investments Inc. purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth about $66,256,000. Thornburg Investment Management Inc. purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth about $48,795,000. Tenzing Financial LLC purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth about $1,345,000. Finally, TritonPoint Partners LLC purchased a new position in Eli Lilly and Company during the fourth quarter valued at approximately $544,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently commented on LLY shares. BMO Capital Markets reaffirmed an "outperform" rating on shares of Eli Lilly and Company in a research note on Monday. Morgan Stanley reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research note on Friday, June 5th. The Goldman Sachs Group reaffirmed a "buy" rating and set a $1,283.00 price objective on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Bank of America boosted their price objective on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a "buy" rating in a research note on Tuesday, May 26th. Finally, Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Eli Lilly and Company in a research note on Monday, June 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $1,227.74.

Eli Lilly and Company Trading Down 0.6%

Shares of Eli Lilly and Company stock opened at $1,122.47 on Wednesday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,182.73. The firm has a market cap of $1.06 trillion, a PE ratio of 39.87, a PEG ratio of 1.23 and a beta of 0.53. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The company has a 50 day simple moving average of $1,006.08 and a two-hundred day simple moving average of $1,016.63.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. During the same period in the previous year, the business posted $3.34 earnings per share. Eli Lilly and Company's revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts expect that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th were given a dividend of $1.73 per share. The ex-dividend date was Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company's payout ratio is presently 24.58%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly announced it is acquiring 4E Therapeutics, a developer of non-opioid pain treatments, expanding beyond obesity and diabetes into the large painkiller market. Investors may view the deal as a strategic move to diversify Lilly’s pipeline and create another long-term growth driver. Lilly buys non-opioid pain drugmaker 4E
• Positive Sentiment: The company also advanced several early-stage programs, including an oral candidate, an Alzheimer’s drug, and other clinical trial updates, which suggests Lilly continues to deepen its pipeline beyond its blockbuster GLP-1 franchise. Eli Lilly Advances New Oral Candidate With Fresh Phase 1 Bioavailability Study
• Positive Sentiment: Broader sector and market commentary remains constructive for GLP-1 leaders like Lilly, with reports projecting strong long-term growth in the global GLP-1 receptor agonist market. Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035
• Neutral Sentiment: Healthcare stocks were broadly firmer in afternoon trading, which may be providing a small tailwind for Lilly alongside the company-specific news. Sector Update: Healthcare Stocks Advance in Afternoon Trading
• Negative Sentiment: Some headlines point to competitive pressure from Novo Nordisk and concerns that Lilly’s GLP-1 drugs could face new reimbursement or demand headwinds, which could temper enthusiasm if those risks grow. Eli Lilly’s hottest drugs face a quiet new threat

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.